Back to search

University of Washington

Dietary Therapy for Pediatric Inflammatory Bowel Disease: An Epidemiologic and Economic Analysis

Abstract

dc:description.abstract

The objective of this study was to assess the potential health outcomes and economic impact of the Specific Carbohydrate Diet (SCD) as a therapeutic option for pediatric patients with inflammatory bowel disease (IBD). In Aim 1, we evaluated the comparative effectiveness of the SCD as an adjunct to pharmacotherapy by using registry data to create an external control arm for an N-of-1 trial. In the full population, there was no statistically significant difference in the change in disease activity from baseline to eight weeks comparing the SCD plus pharmacotherapy to pharmacotherapy alone. In subgroup analyses limited to patients with active disease at baseline, the difference in differences in disease activity was statistically significant, but did not reach clinical significance. In Aim 2, we developed a hybrid decision tree Markov model to assess the value-based price (VBP) of the SCD for induction of remission in pediatric patients with active Crohn’s disease (CD). At an effectiveness of only 50%, we found that the VBP of the SCD at a willingness-to-pay threshold of $50,000 per quality-adjusted life year was close to $20,000, which far exceeds the likely cost of the diet. In Aim 3, we conducted a qualitative study of parents of patients with IBD treated at Seattle Children’s Hospital to assess perceived barriers to initiating and/or maintaining the SCD. We found that parents of children diagnosed with IBD primarily chose to try the SCD due to concerns about medication safety. Additionally, we identified that cost, time commitment, and psychosocial impact are three major barriers to utilizing the SCD. This work provides a foundation for further research into the population health and economic impacts of dietary therapy for IBD. Future studies are needed to assess both the direct and indirect costs of the SCD, as well as the effectiveness of the SCD as a stand-alone therapy and as an adjunct to pharmacotherapy. These data would enable more robust evaluation of the SCD as a therapeutic option, therefore providing essential information for clinicians, patients, payers, and policy-makers.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Schwartz, Naomi Rose Maas
Advisor dc:contributor.advisor
  • Devine, Beth

Subjects

dc:subject × 4

Rights

dc:rights
Statement dc:rights
  • none
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1773/48176

Chain of custody

source
Harvested from
University of Washington
Base URL
digital.lib.washington.edu/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Schwartz, Naomi Rose Maas. Dietary Therapy for Pediatric Inflammatory Bowel Disease: An Epidemiologic and Economic Analysis. 2022. http://hdl.handle.net/1773/48176